IDXX vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 26, 2026

IDXX

63.1
AI Score
VS
IDXX Wins

MRNA

40.7
AI Score

Investment Advisor Scores

IDXX

63score
Recommendation
HOLD

MRNA

41score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric IDXX MRNA Winner
Forward P/E 31.4465 23.0415 MRNA
PEG Ratio 2.8525 0 Tie
Revenue Growth 9.7% 2.1% IDXX
Earnings Growth 17.6% -85.1% IDXX
Tradestie Score 63.1/100 40.7/100 IDXX
Profit Margin 25.0% -141.4% IDXX
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

IDXX 1M: -2.6% · 3M: -9.3% MRNA 1M: +40.0% · 3M: +156.6%

Current Technical Phase

IDXX

Markdown
Sell / avoid

Price below a falling SMA50 (slope -2.8%), weak momentum, RSI 40

RSI (14): 40.2 · Price: $506.67

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (49.6% over 20 days), RSI 64

RSI (14): 63.6 · Price: $196.48

Fundamentals Snapshot

Metric IDXX MRNA
Market Cap — —
Forward P/E 30.3 -41.0
Trailing P/E 37.0 —
Revenue (TTM) — —
Revenue Growth 0.1% 0.0%
Gross Margin 0.6% -0.7%
Operating Margin 0.3% -5.6%
EPS 13.92 -7.36
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, IDXX is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.